BGT-1 CRISPR/Cas9 KO Plasmid (m): sc-420468
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BGT-1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the BGT-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BGT-1 Antibody (D-5): sc-514024
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BGT-1 CRISPR/Cas9 KO Plasmid (m) | sc-420468 | 20 µg | $397.00 |
Overview
Slc6a12 encodes the betaine/GABA transporter BGT-1 (SLC6A12), a Na⁺/Cl⁻-dependent member of the SLC6 neurotransmitter transporter family that mediates cellular uptake of the osmolyte betaine and can transport GABA in select contexts. BGT-1 contributes to osmotic stress adaptation and cell volume regulation by supporting intracellular organic osmolyte accumulation, linking membrane transport to osmoprotective programs and metabolic homeostasis. In mouse tissues, Slc6a12 expression has been studied in kidney epithelia and within the nervous system, where altered transporter activity may influence inhibitory tone and stress-responsive signaling. Dysregulation of osmolyte handling and GABAergic balance is relevant to models of renal osmotic injury, neuroinflammation, and seizure susceptibility, making Slc6a12 a useful target for mechanistic pathway studies.
BGT-1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Slc6a12 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Slc6a12 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Slc6a12 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BGT-1 protein expression.
This CRISPR knockout system enables efficient generation of Slc6a12-deficient cell models for investigation of BGT-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Slc6a12 exon(s) critical for BGT-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Slc6a12 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by BGT-1 CRISPR/Cas9 KO Plasmid (m) and BGT-1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Slc6a12 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by BGT-1 HDR Plasmid (m) and BGT-1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Slc6a12 homology arms to support homology-directed repair at defined Slc6a12 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.